Skip to Main Content

It’s do-or-die time for Sage Therapeutics (SAGE).

The failure of the brexanolone phase 3 clinical trial in severe epilepsy announced Tuesday bent, but did not break, Sage’s stock price. The company is getting a second chance to prove the therapeutic value of brexanolone with two phase 3 studies in women with postpartum depression.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!